针对转移性神经内分泌肿瘤的强化肝导向放射性核素疗法显示出前景
Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors
研究通过结合肝动脉和静脉给药方式,对10名患者进行了四次周期性治疗,结果显示强化肝导向PRRT疗法在治疗晚期神经内分泌肿瘤方面有效,部分缓解率从67%提高到87%。
研究探索了一种新的肝导向PRRT疗法,显示了对晚期神经内分泌肿瘤的有效性。
Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body. This hybrid approach safely delivered over three times more radiation directly to liver metastases, resulting in encouraging tumor responses among patients. This research was published online in the Journal of Nuclear Medicine.
Once considered rare, gastroenteropancreatic NETs now show increasing incidence and prevalence. Diagnosis often occurs late, usually with liver metastases, making surgery—the only curative option—unfeasible. Current liver-directed (or hepatic) therapies, such as systemic agents, chemotherapy and PRRT, offer symptom and tumor control, with a median progression-free survival of approximately 1.5 years.
"Research has shown that standard intravenous PRRT may not deliver enough radiation to these lesions," said Lisa Bodei, M.D., Ph.D., attending physician, member and director of RadioTheranostics Section, Molecular Imaging and Theranostics Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center and professor of radiology at Weill Cornell Medical College of Cornell University, in New York.
"Our study explored a personalized hybrid approach—delivering the first treatments directly through hepatic arteries, followed by intravenous therapy—and sought to determine if this treatment method was feasible, safe and effective."
The prospective pilot study included 10 patients with progressive, liver-dominant metastatic gastroenteropancreatic NETs. The patients received four cycles of ¹⁷⁷Lu-DOTATATE administered every two months: two initial intraarterial cycles followed by two intravenous cycles. Safety monitoring, radiation protection and dosimetry comparisons between intraarterial and intravenous routes were performed, and preliminary efficacy was evaluated.
The intraarterial administration procedure was feasible in 100% of patients. Radiation exposure to staff and patients remained within regulatory limits, with no contamination events. Dosimetry analysis indicated that intraarterial administration delivered a greater than threefold higher radiation dose to liver metastases compared with the intravenous route.
Furthermore, ⁶⁸Ga-DOTATATE PET imaging revealed an 86% increase in median liver lesion uptake with intraarterial administration. Efficacy analysis showed partial response rates in 67% of patients at the first follow-up three months after treatment completion, improving to 87% at the second follow-up six months after treatment completion.
"The novelty of this research is not simply that liver-directed intraarterial PRRT increases hepatic uptake; rather, it evaluates a clinically integrated, personalized hybrid strategy that links delivery, dosimetry, safety and response within the same prospective study," said Bodei. "For patients, this could translate into better tumor control and a more effective, individualized treatment option."
Publication details
Lisa Bodei et al., Optimizing the Therapeutic Index: Sequential Intraarterial–Intravenous PRRT with Personalized Volumetric-Adjusted Dosing, Journal of Nuclear Medicine (2026). DOI: 10.2967/jnumed.126.272710
Journal information: Journal of Nuclear Medicine
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors (2026, November 13) retrieved 13 November 2026 from https://medicalxpress.com/news/2026-11-liver-radionuclide-therapy-patients-metastatic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com